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Multiply-primed rolling circle ampliﬁcation (RCA) is a suitable technique for ampliﬁcation of circular
templates and has been used to identify novel human papillomaviruses (HPV). In this study we develop
an efﬁcient RCA for whole genome ampliﬁcation of HPV using HPV-speciﬁc primers in clinical samples
and establish a protocol for whole genome sequencing using the Sanger method. Ampliﬁcation of
cloned HPV-genomes by RCA was compared using speciﬁc primers against random hexamers. Using
HPV-speciﬁc primers increased the effectiveness on average 15.2 times and the enrichment of HPV
relative to human gDNA on average 62.2 times, as compared to using random hexamer. RCA products
were sequenced without need for cloning, even when using low-input amounts. The technique was
successfully used on 4 patient samples from FTA cards, to generate whole HPV-genome sequences.
Degenerated HPV-speciﬁc primers for RCA produce DNA of sufﬁcient quality and quantity suitable for
sequencing and other potential downstream analyses.
& 2012 Published by Elsevier Inc.Introduction
Persistent infection with certain types of human papilloma-
virus (HPV) is the leading risk factor for cervical cancer (Bosch
et al., 1995; Munoz et al., 2003; Walboomers et al., 1999). This
group of virus contains over 200 different types, both oncogenic
and non-oncogenic, yet new variants continue to be discovered
(de Villiers et al., 2004; Lizano et al., 2009).
Multiply-primed rolling circle ampliﬁcation (RCA) enables
ampliﬁcation of circular templates, making it suitable for ampli-
ﬁcation of circular viral genomes in a background of genomic DNA
(Dean et al., 2001;Johne and Muller, 2009; Nelson et al., 2002).
This method has led to the discovery of new virus types, including
members of the papillomavirus family (Johne et al., 2006;
Margeridon et al., 2008; Niel et al., 2005; Rector et al., 2004a,
2005; Tobler et al., 2006; Xu et al., 2008). The RCA is an
isothermal DNA synthesis reaction which uses the phi29 DNA
polymerase. This polymerase has a 50- to -30 polymerization
activity and a 30- to -50 ssDNA exonucleolytic activity, which
provides a proofreading-ability. Phi29 also has a strong strand
displacement activity (Blanco et al., 1989) that allows for the
complementary strand to be displaced during replication, consis-
tently creating a new template for the ampliﬁcation. The mostElsevier Inc.
y, Genetics and Pathology,
niversity, S-751 85 Uppsala,
stavsson).widely used kit for RCA (Illustra TempliPhi, GE Healthcare Life
Sciences) utilizes exonuclease-resistant random hexamers, how-
ever a recent study reported that the ampliﬁcation of HPV DNA
using TempliPhi could be improved by addition of nucleotides,
since they were quickly depleted during the ampliﬁcation process
(Rector et al., 2004b).
The use of random hexamers offers the possibility to amplify
circular templates without any prior knowledge of the sequence,
which has been advantageous in the discovery of new virus types.
Consequently, this increases the risk of background ampliﬁcation
of other confounders present in the same sample, such as human
genomic DNA. By designing degenerated HPV-speciﬁc primers
using alignments for genital HPV types, we were able to increase
the effectiveness of the RCA and the enrichment of HPV relative to
human genomic DNA, as compared to using random hexamers.
The RCA product was successfully sequenced without the need for
cloning even when amplifying small amount of HPV-plasmid. We
found this technique to be suitable for ampliﬁcation of HPV DNA
extracted from clinical FTA cards, providing sufﬁcient template
for subsequent Sanger sequencing to generate whole HPV genome
sequences.Results
Rolling circle ampliﬁcation of HPV DNA
HPV-plasmids were used to evaluate the ampliﬁcation
efﬁciency of the RCA, and in order to mimic clinical samples,
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electrophoresis of digested HPV-RCA products showed the
presence of a fragment of the size expected for the entire
HPV35-genome including the plasmid vector. RCA products were
obtained for a range of starting amounts (Fig. 1A) and veriﬁed to
be HPV35 using RT-PCR (data not shown). Detectable levels of
HPV DNA were obtained after 4 h of incubation; however levels
increased considerably after 18 h. Two negative controls were
also incubated for either 4 or 18 h and veriﬁed using RT-PCR (data
not shown). Negative control 1, containing only background
gDNA, produced a smear that was enhanced after 18 h of incuba-
tion due to lack of competition against HPV DNA for the primers
used in RCA (Fig. 1A). In negative control 2, no ampliﬁcation
product was seen after RCA (Fig. 1A). The HPV-RCA was able to
amplify a series of HPV types (HPV16, -18, -54, -56), representing
different HPV groups (Fig. 1B). These HPV-RCA products were
sequenced using Protocol A and analyzed using BLAST. In each
case the expected HPV sequence was detected (data not shown).
To evaluate the speciﬁcity of the HPV-RCA, as compared to
random hexamer-RCA, we studied serial 10-fold dilutions of
HPV35-plasmid in a background of 10 ng of high-molecular
weight human gDNA. Product were digested and the number of
HPV and human gDNA copies determined by RT-PCR (Gustavsson
et al., 2009a). Average enrichment by the HPV-RCA was 4.9105-fold
as compared to a 3.2104-fold enrichment for hexamer-RCA. This
represented a 15.2 times higher enrichment when using HPV-RCA
(Fig. 2A). The enrichment of HPV DNA relative to human gDNA wasFig. 1. RCA of HPV-plasmids using HPV-speciﬁc primers. (A) Concentrations of
HPV35-plasmid ranging from 100 ng to 12.5 ng were used as template for RCA.
Negative control 1 (Neg 1) contained 10 ng of gDNA and no HPV35 DNA, whereas
negative control 2 (Neg 2) contained no DNA at all. Ampliﬁcation was performed
at 30 1C for either 4 or 18 h. (B) The degenerated HPV-speciﬁc primers were tested
on HPV-plasmids from different species groups using 3 ng as template for RCA,
and ampliﬁed for 18 h. L, 1 kb DNA ladder.
Fig. 2. Ampliﬁcation efﬁciency of the RCA assays. A serial 10-fold dilution of
HPV35-plasmid mixed with human genomic DNA was ampliﬁed using HPV-
speciﬁc primers (HPV-RCA) and compared to ampliﬁcation performed with
random primers (hexamer-RCA). The number of HPV copies and copies of a
single-copy human gene were quantiﬁed before and after RCA using real-time
PCR. (A) Fold enrichment of HPV35 for samples ampliﬁed either with HPV-RCA or
hexamer-RCA. (B) Relative enrichment for HPV35 for samples ampliﬁed with HPV-
RCA as compared to hexamer-RCA.on average 1.5105-fold for HPV-RCA as compared to a 2.4103-
fold when using hexamer-RCA (Fig. 2B).
Evaluation of mixed infection
To study RCA in samples containing multiple HPV types,
plasmids containing HPV18 and HPV52 genomes were mixed in
the ratios 1:1 (HPV18: HPV52), 4:1 (HPV18: HPV52) and 4:1
(linearized HPV18: circular HPV52). Pooled samples were used in
the HPV-RCA, RE digested and the HPV copy numbers estimated
by RT-PCR. Samples with a 1:1 ratio prior to RCA (Table 2:
samples 1–3) showed a shift in ratio to 0.3:0.7, reﬂecting a
preferential ampliﬁcation of HPV52, although both HPV types
were detectable. Samples with a ratio of 4:1 between HPV18 and
HPV52 prior to RCA showed a ratio of 0.6:0.4, due to preferential
ampliﬁcation of HPV52, although the amount of HPV18 was still
slightly higher than HPV52 (Table 2; samples 4–6). In the ﬁnal
series, a ratio of 4:1 between HPV18 and HPV52 prior to RCA was
also used but the HPV18-plasmid was linearized by RE digest
prior to mixing with HPV52. The amount of HPV18 after HPV-RCA
was considerably reduced with HPV52 dominating (498%)
(Table 2; samples 7–9).
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The sequencing protocol was developed using 10-fold dilu-
tions of HPV35-plasmid and included sequencing with two
reverse and two forward primers. For each sample, four indepen-
dent sequencing reactions were performed and average read
length was calculated. RCA products from samples with high
HPV copy numbers could be sequenced directly by diluting the
product 60 times (Protocol A) (Table 3; samples 1 and 2). As input
HPV copy numbers decreased below 105 copies the read length
was shortened. Since the product obtained from RCA is concate-
meric, high-molecular weight, linear, dsDNA, we hypothesized
that this complex structure impeded the annealing of sequencing
primers. By using RE digested RCA samples we were able to
obtain high quality sequences using Protocol B from as little as
14,000 copies (0.2 pg) of HPV35-plasmid. When even lower copy
numbers were used poor sequence results were obtained (Table 3,
sample 6).
HPV35-genome diversity
The optimized HPV-RCA protocol was evaluated using four
clinical samples known to be infected solely with HPV35. Samples
varied in copy numbers (104–106), and hence were treated with
either Protocol A or B prior to sequencing. To ensure that the HPV-
RCA method did not introduce artefact substitutions, two inde-
pendent HPV-RCAs were performed from the same DNA sample
for individuals 1 (GenBank accession No. JX129485), 2 (GenBank
accession No. JX129486) and 3 (GenBank accession No. JX129487)
and each used to determine the full HPV-genome. Plus and minus
strands were sequenced separately for the two independent RCA-
samples and identical HPV sequences were obtained (Fig. 3). For
individual 3 we also sequenced the full genome from the same
RCA using either the plus or minus strand (3.1R and 3.1F) to
conﬁrm that Sanger sequencing did not introduce any sequence
artefacts (Fig. 3); identical HPV sequences were obtained (Fig. 3).Fig. 3. Genome sequence diversity of HPV35. Four clinical samples were ampliﬁed usi
and sample 4 was collected in South Africa. For samples 1 and 2, two independent HPV-
(F) or reverse (R) primers. For sample 3, two RCAs were also performed; one was seq
forward (3.1F) primers. Nucleotide substitutions are shown by the base affected, dele
insertions. Amino acid exchanges (AA) relative to the reference are indicated above eaSample 4 (GenBank accession No. JX129488) was only sequenced
for the minus strand. We found that all the samples differed from
the HPV35 reference by nucleotide substitutions, deletions or
large insertions. We detected a previously characterized insertion
of 16 bp in the long control region (LCR) in two of the samples
(Fig. 3; individuals 1 and 2). Consistent with previous studies
which reported that this insertion is less common in African
populations, we did not detect this in individual 4 (Calleja-Macias
et al., 2004, 2005). A large deletion of 74 bp located in the LCR was
also found in individual 1. The HPV35 sequence from individual 4,
of South African origin, differs considerably from that of the three
Swedish women, consistent with previous studies of some
regions of HPV35 that have shown variation between populations
(Calleja-Macias et al., 2004, 2005). We found a total of 19
nucleotide substitutions which resulted in amino acid changes
and these affected all of the coding regions except E7 (Fig. 3).Discussion
We have shown that the use of degenerated HPV-speciﬁc
primers enhances the efﬁciency of the RCA up to 15.2 times as
compared to random hexamers. Enrichment of the HPV-genome
relative to human gDNA was also drastically enhanced. The HPV-
RCA system successfully ampliﬁed HPV types from different
species groups, supporting the utility of this system for a range
of HPV types.
In order to evaluate the ampliﬁcation efﬁciency of samples
infected with multiple HPV types we studied synthetic mixtures
of HPV-plasmids. The RCA successfully ampliﬁed both HPV types
in a mixture, although with a slight preference for HPV52. In
clinical samples with multiple infections, the ratio of HPV types
may vary extensively, and our results indicate that for very skewed
ratios, the lower frequency HPV type may be lost in the HPV-RCA.
However, if typing information is available, one strategy to remove
the effect of a type present at a high frequency is to linearize thisng HPV-RCA and their genome sequenced. Samples 1–3 were collected in Sweden
RCA reactions were performed for each sample and either sequenced using forward
uenced by the reverse primers (3 R) and the other using either reverse (3.1R) or
tions by a hyphen and insertions by a white square for individuals lacking these
ch nucleotide substitution.
Table 1
Degenerated HPV-speciﬁc primers for RCA.
Primer namea Sequenceb
E6 412F 50–AATAAGGTnGnY-30
E7 635R 50–AATTGCTCnYnT-30
E1 1257R 50–GCCATATCCYnCnT-30
E1 1881F 50–CCAGARTGnGnA-30
E1 2085R 50–TGTCTYCACnAnT-30
E1 2329F 50–TTKGAATGnAnG-30
E1 2374F 50–TATGTAAAYnTnC-30
E1 2484R 50–GYTTTCCAnTnC-30
E4 3356F 50–TCTGTRTCYnAnG-30
E4 3367R 50–AGCAGTGGYnTnA-30
E2 2773R 50–GCATRTAAAnCnG-30
E2 2933F 50–CAGGTGGTGnCnC-30
L2 4824F 5’–GAAGAAATWnCnC-30
L2 4991R 50–GCAGGATTYTnCnA-30
L2 5102R 50–GCTGGCCTYnTnG-30
L2 5617F 50–CCGTAAACnGnT-30
L2 5639F 50–TTTGCAGAnTnG-30
L1 6236F 50–GATGGTGAYAnTnG-30
L1 6327R 50–ATAATCWGGAnTnA-30
L1 6364F 50–GATCCATATnGnG-30
L1 6597R 50–CAAATYCCAnTnT-30
L1 6646F 50–GTAGATACYnAnC-30
L1 6763R 50–CACAARTGnAnA-30
a Primers were named by the location on the gene,
number of 30 nucleotide of the HPV16 genome and primer
direction (F, forward; R, reverse).
b Degenerated primers were used (Y¼T or C; R¼A or
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strategy to be quite efﬁcient by linearizing HPV18 prior to RCA,
resulting in a large excess of HPV52 as compared to o2% of HPV18.
This strategy depends on the presence of a RE site that is unique for
the major type.
Two protocols for sequencing of the RCA products were devel-
oped. High-copy number samples were simply diluted after RCA,
whereas low-copy number samples were RE digested and cleaned
before sequencing. As low as 14,000 copies of HPV-plasmid was
successfully sequenced using Protocol B. Even lower copy numbers
(1200) were possible to sequence, but with reduced quality and
read length. Clinical samples were also ampliﬁed by HPV-RCA,
generating high-quality genome sequences, and demonstrated the
use of the FTA cards for large-scale studies. Comparison of the full
genome sequence from independent HPV-RCA reactions generated
from the same DNA sample, shows that the method is robust and
does not introduce false substitutions. Comparison of clinical
samples infected by HPV35 revealed a number of polymorphic
sites, several of which have not previously been described and
resulting in substitutions that alter the amino acid sequence.
Furthermore, a previously characterized insertion of 16 bp in the
LCR was found in two samples. In summary, the HPV-RCA results
in an effective ampliﬁcation of the full HPV-genome, with sufﬁcient
quantity and quality for full genome sequencing, even for clinical
samples with low levels of oncogenic forms of HPV. Thus, this
method is suitable for large-scale full-genome sequencing of
oncogenic forms of HPV in clinical samples.G; K¼G or T; W¼T or A). The position of the thiopho-
sphate modiﬁcation is marked with n.
Table 2
RCA of synthetic HPV-plasmid mixtures. HPV18- and HPV52-plasmid were mixed
in a ratio of 1:1 (samples 1–3), 4:1 (samples 4–6) or 4:1 using linearized HPV18
(samples 7–9). Plasmid mixtures were submitted to RCA using speciﬁc primers.
Sample Percentage before RCA Percentage after RCA
HPV18 (%) HPV52 (%) HPV18 (%) HPV52 (%)
1 53 47 33 67
2 50 50 29 71
3 50 50 18 82
4 84 16 63 37
5 79 21 54 46
6 83 17 56 44
7a 82 18 2 98
8a 81 19 1 99
9a 85 15 1 99
a Mixtures were performed using linearized HPV18-plasmid.
Table 3
Features of the sequence reads obtained from RCA products, when using either
Protocol A or Protocol B prior to the Sanger method.
Sample Number of HPV35
copies used as
input for RCA
Protocol
used prior
sequencing
Average
length per
samplea
Average base
number with a
quality score of 20b
1 108 Protocol A 809 770
2 107 Protocol A 826 789
3 106 Protocol B 891 852
4 105 Protocol B 710 662
5 104 Protocol B 653 609
6 103 Protocol B 106 81
a The average length of four runs is used for every sample.
b This column displays the number of bases witho1 in 100 error probability,
as deﬁned by the CodonCode software.Materials and methods
HPV DNA samples
Plasmids containing the HPV16, 18, 35, 52, 54, and
56 genomes were used for optimization of the RCA (Moberg
et al., 2003). Patient samples (n¼4), previously identiﬁed as solely
positive for HPV35 were studied (Gustavsson et al., 2009a). Three
samples were from women attending gynecological screening in
Uppsala, Sweden. This screening system is based on sample
collection using a cytobrush and applied to a ﬁlter paper matrix,
the indicating FTA elute micro card (WB 120411, GE Healthcare,
United Kingdom) (Gustavsson et al., 2009b). The fourth sample
was from a black South African woman collected using a Digene
cervical sampler (Mbulawa et al., 2010).
Multiply-primed RCA
Alignments of genital HPV-genomes were generated from a
HPV-sequence database (http://hpv-web.lanl.gov/, version 1997)
and degenerated ampliﬁcation primers were designed to cover
well-conserved regions. Primers were protected by a thiopho-
sphate modiﬁcation between the last two nucleotides at the 30
end which increases their stability during RCA. The RCA (termed
HPV-RCA) contained a premix of 23 HPV-speciﬁc primers
(Table 1) at a ﬁnal concentration of 0.4 mM each, 1X phi29 DNA
polymerase buffer, 10 ng of human gDNA and dH2O in a ﬁnal
volume of 10 ml. When amplifying patient samples the same
reaction mix was used except that no human gDNA was added
to the premix and the ﬁnal volume was adjusted with water.
Subsequently, 2 ml of DNA (plasmid or patient sample) was added
to the premix, at varying concentrations ranging between
102–109 HPV copies. Two negative controls were used by adding
2 ml dH2O as template, with one of the controls containing 10 ng
of human gDNA (Negative 1) and the other containing no human
gDNA (Negative 2). The DNA mixture including the HPV-speciﬁc
primers, was denatured at 95 1C for 3 min and then cooled to 4 1C
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of the ampliﬁcation solution which contained the 23 HPV-speciﬁc
primers at a ﬁnal concentration of 0.4 mM each, 1X phi29 DNA
polymerase buffer, 2 ng/ml bovine serum albumin (BSA), 15 mM
dNTPs, 2 U/ml of phi29 DNA polymerase (Thermo Scientiﬁc,
Fermentas, Sweden) and dH2O. For samples with low-copy
numbers collected from the FTA cards, the concentration of BSA
was increased to 0.4 mg/ml. The sample was incubated at 30 1C
for either 4 or 18 h, followed by inactivation of the enzyme at
65 1C for 10 min and then stored on ice. To evaluate the speciﬁc
primers ability to reduce the background of human gDNA, an
additional protocol (termed hexamer-RCA) was prepared by
substituting the HPV-speciﬁc primers for 10 mM phosphorothio-
ate modiﬁed random primers (hexamers) (Thermo Scientiﬁc,
Custom Biopolymers, Germany); RCA was performed as described
previously.Restriction enzyme digestion of RCA product
The RCA product was digested with a restriction enzyme (RE)
which cut the HPV-genome once. Ten ml of RCA product was
added to 20 ml digestion mix containing 0.7 U/ml RE, 1x RE buffer
and dH2O and incubated at 37 1C for 16 h, with a further 2 ml RE
added after 2 h. Two ml of the digested RCA product was analyzed
by electrophoresis on a 0.8% agarose gel stained with SYBRs Safe.Real-time PCR assay
Type identiﬁcation and quantiﬁcation of the HPV copy number
was performed using a real-time PCR assay (RT-PCR) (Gustavsson
et al., 2009a). This assay detects 12 high-risk HPV types and
quantiﬁes a human single copy gene, hydroxymethylbilane
synthase. For each reaction, 3 ml of diluted RE sample was used
and the quantiﬁcation was performed as previously described
(Gustavsson et al., 2009a). To calculate the fold enrichment of
HPV, the number of copies obtained after RCA was divided by the
number of copies used as templates in the RCA. To determine the
relative enrichment of HPV compared to human gDNA, the fold
enrichment of HPV was divided by the fold enrichment of
human gDNA.Sequencing of RCA product
Two different protocols were used for the sequencing of RCA
products. Protocol A was used for samples with greater than 106
copies prior to ampliﬁcation, and was based on a 60-fold dilution
of the RCA product and subsequent direct sequencing. Protocol B
was used for samples with less than 106 copies prior to RCA. Each
RCA product to be sequenced was RE digested and puriﬁed using
1 U Shrimp Alkaline Phosphatase and 10 U Exonuclease I (Thermo
Scientiﬁc, Fermentas, Sweden) per 5 ml template. Incubation was
at 37 1C for 15 min, followed by inactivation at 85 1C for 15 min.
Sequencing was performed with BigDyes Terminator v3.1 chem-
istry (AB Applied Biosystems), using 3 ml DNA and 1.6 pmol of
HPV35-speciﬁc primers (designed with Primer3 software, http://
ﬂypush.imgen.bcm.tmc.edu/primer/). The sample was further
puriﬁed by ethanol precipitation and analyzed on the ABI3730XL
DNA Analyzer. Sequences were aligned against a reference HPV35
sequence (accession number: X74477) and quality of reads were
obtained using the CodonCode software (version 3.7.1). The
sequences described in this report were deposited in GenBank
under the accession number JX129485, JX129486, JX129487 and
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